🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our phase 3 trial data for CAN-2409 in prostate cancer will be presented at #ASCO2025 by Dr. DeWeese, Dean of Medical Faculty & CEO at Johns Hopkins. The findings represent the first potential new treatment for localized prostate cancer in over 20 years. ir.candeltx.com/news-releases/…

Thank you to everyone who joined us for our event at the historic Glessner House during ASCO 2025! It was a wonderful opportunity to connect with colleagues, share our excitement about the positive CAN-2409 phase 3 prostate cancer data, and celebrate this milestone together.

#ICYMI: FierceBiotech covered how our CAN-2409 lung cancer survival data is lighting the path toward a pivotal trial in nonsquamous NSCLC patients, who showed remarkably strong disease control with median OS of 25.4 months. fiercebiotech.com/biotech/candel…

During #MensHealthWeek, we reflect on our commitment to developing treatments for prostate, lung, & pancreatic cancer. Our experimental medicines show promising results with potential to transform treatment paradigms & offer hope for patients with difficult-to-treat solid tumors.

Join our CSO, Francesca Barone, M.D., Ph.D., as she participates in a webinar with Cell & Gene. Candel brings expertise across two clinical-stage viral platforms: adenovirus (CAN-2409) & HSV (CAN-3110), plus our enLIGHTEN™ Discovery Platform. Tune in: event.on24.com/wcc/r/4954402/…

Last week we announced the appointment of Maha Radhakrishnan, M.D., to our Board of Directors! Maha brings 20+ years of biotech leadership experience in product development & commercialization. ir.candeltx.com/news-releases/… #Leadership #CancerTherapeutics $CADL

Read how Candel is advancing cancer immunotherapies through our viral delivery platform in this Drug Discovery World interview with our CEO Dr. Paul Peter Tak. Our approach teaches immune cells to recognize and attack cancer cells directly in tumors. ddw-online.com/gene-delivery-… $CADL

We're proud to see CAN-2409's promising results in Labiotech.eu on the future of #NSCLC treatment! Our phase 2a results showed 24.5 months median overall survival in advanced NSCLC patients who had an inadequate response to immune checkpoint inhibitors. labiotech.eu/in-depth/futur…

Pharma Features spoke to our CTDO, Dr. Tyagarajan! She discusses how her cross-platform expertise supports the advancement of Candel's leading adenoviral platform, HSV platform, and enLIGHTEN™ Discovery Platform. Read here: pharmafeatures.com/enhancing-anal…

We're pleased to announce Charles Schoch as our new CFO! His understanding of our business will be instrumental as we advance our clinical pipeline, prepare for BLA submission for CAN-2409 in localized prostate cancer, and execute on corporate goals. ir.candeltx.com/news-releases/…

We're pleased to announce a $15M registered direct offering to advance pre-commercialization activities for CAN-2409 in prostate cancer. Supported by existing institutional investors and company leadership as we work to transform cancer treatment. ir.candeltx.com/news-releases/…

Thank you HemOnc Today for featuring our phase 2 trial of CAN-2409, showing 24.5 month median OS in advanced #NSCLC patients with an inadequate response to immune checkpoint inhibitors. Particularly encouraging results in nonsquamous histology patients. healio.com/news/hematolog…

Wishing everyone a fun and safe 4th of July holiday. Happy Independence Day! #IndependenceDay #4thofJuly

#ICYMI: FierceBiotech highlighted our successful phase 3 prostate cancer trial. The study demonstrated a statistically significant 30% reduction in disease recurrence risk fiercebiotech.com/biotech/candel… #ProstateCancer $CADL

We're pleased to be added to multiple Russell Value indexes in 2025 reconstitution, including Russell 2500 Value, Small Cap Value, 2000 Value, Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell 3000 Index. ir.candeltx.com/news-releases/… $CADL

Thanks Labiotech.eu for featuring us in a lung cancer companies article! CAN-2409 achieved 24.5 months median overall survival (mOS) in #NSCLC with an inadequate response to ICIs, markedly better than mOS in published control patients treated with chemo. labiotech.eu/best-biotech/l…

Today is #GlioblastomaAwarenessDay. We honor those lost to GBM & stand with patients, families & caregivers affected. At Candel, we're advancing CAN-3110, a first-in-class, next generation viral immunotherapy for recurrent high-grade glioma. braintumor.org/events/gliobla… #GBMDay

Throwback to Kyle's inspiring 2023 story on WCVB about how a clinical trial of CAN-3110 gave her ‘the gift of time’, living with glioblastoma. Her journey inspires us to advance CAN-3110 for recurrent high-grade glioma. Watch: wcvb.com/article/boston… #BrainCancer #GBMDay $CADL

#ICYMI @BradLoncar at BiotechTV and our CEO, Dr. Paul Peter Tak, discussed CAN-2409's phase 3 prostate cancer data and our strategy across multiple solid tumors at #ASCO25! Watch: biotechtv.com/post/candel-th…

Exciting milestone! The EMA granted Orphan Drug Designation for CAN-2409 in pancreatic cancer. This adds to our FDA Orphan Drug & Fast Track Designations, reinforcing the unmet need in this disease. ir.candeltx.com/news-releases/… $CADL